ArticleFrontiers in bioengineering and biotechnology2020
Engineering Immunomodulatory Biomaterials for Regenerating the Infarcted Myocardium.
Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Key Steps in Murine Cardiac Engineering Validation: How Does It Affect the Efficiency of Cardiac Devices?BioMed research international · 2026Review
- Angiogenesis: Biological Mechanisms and In Vitro Models.Annals of biomedical engineering · 2025Review
- Review
- Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches.Drug delivery and translational research · 2023Review
- Mending a broken heart by biomimetic 3D printed natural biomaterial-based cardiac patches: a review.Frontiers in bioengineering and biotechnology · 2023Review
- Harnessing Biomaterials for Immunomodulatory-Driven Tissue Engineering.Regenerative engineering and translational medicine · 2023Review
- Immunomodulating Hydrogels as Stealth Platform for Drug Delivery Applications.Pharmaceutics · 2022Review
- Microbial resistance to nanotechnologies: An important but understudied consideration using antimicrobial nanotechnologies in orthopaedic implants.Bioactive materials · 2022Review
- Recent Advances in Designing Electroconductive Biomaterials for Cardiac Tissue Engineering.Advanced healthcare materials · 2022Review
- Lipidome profiling with Raman microspectroscopy identifies macrophage response to surface topographies of implant materials.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Heparin-modified alginate microspheres enhance neovessel formation in hiPSC-derived endothelial cells and heterocellular in vitro models by controlled release of vascular endothelial growth factor.Journal of biomedical materials research. Part A · 2021Article
- Implant Fibrosis and the Underappreciated Role of Myofibroblasts in the Foreign Body Reaction.Cells · 2021Review
- Polymeric Biomaterials for the Treatment of Cardiac Post-Infarction Injuries.Pharmaceutics · 2021Review
- Cardiac mechanostructure: Using mechanics and anisotropy as inspiration for developing epicardial therapies in treating myocardial infarction.Bioactive materials · 2021Review
- Assessing the Angiogenic Efficacy of Pleiotrophin Released from Injectable Heparin-Alginate Gels.Tissue engineering. Part A · 2021Article
- Review
- Self-Healing, Stretchable, Biocompatible, and Conductive Alginate Hydrogels through Dynamic Covalent Bonds for Implantable Electronics.Polymers · 2021Article
- Cardiac fibroblast derived matrix-educated macrophages express VEGF and IL-6, and recruit mesenchymal stromal cells.Journal of immunology and regenerative medicine · 2020Article
- Preparation and Evaluation of Sustained Release Platelet-Rich Plasma-Loaded Gelatin Microspheres Using an Emulsion Method.ACS omega · 2020Article
- Engineered human myocardium with local release of angiogenic proteins improves vascularization and cardiac function in injured rat hearts.Biomaterials · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Coronary artery disease is a severe ischemic condition characterized by the reduction of blood flow in the arteries of the heart that results in the dysfunction and death of cardiac tissue. Despite research over several decades on how to reduce long-term complications and promote angiogenesis in the infarct, the medical field has yet to define effective treatments for inducing revascularization in the ischemic tissue. With this work, we have developed functional biomaterials for the controlled release of immunomodulatory cytokines to direct immune cell fate for controlling wound healing in the ischemic myocardium. The reparative effects of colony-stimulating factor (CSF-1), and anti-inflammatory interleukins 4/6/13 (IL4/6/13) have been evaluated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.